Tao Synergies Inc. · NASDAQ:TAOX
Tao Synergies — NanoVibronix — Investor Presentation (March 2019)
14 slides from Tao Synergies's investor presentation, Mar 11, 2019
Slide 1: Prevention of Bacterial Load and CAUTI Through Surface Acoustic Waves on Indwelling Catheters
An effective Solution for the Prevention of Bacterial Load and CAUTI, Through the Application of Surface Acoustic Waves on Indwelling Catheters March 11, 2019 NASDAQ : NAOV
Slide 2: Disclaimer
This presentation contains forward - looking statements. Forward - looking statements are based on current expectations and projections about future events and are subject to risks, uncertainties and assumptions about our Company, economic and market sectors and the industry in which we do business,
Slide 3: NanoVibronix Shield platform delivers surface acoustic waves
NASDAQ: NAOV The NanoVibronix “Shield” platform delivers surface acoustic waves (SAW) to soft tissue , muscle , and indwelling devices is designed to : – Prevent microbial colonization and disrupts biofilm formation on indwelling devices – Provide a unique enhancement for antibiotic effectiveness –
Slide 4: UroShield
NASDAQ: NAOV • A therapeutic surface acoustic wave device, consisting of a reusable driver unit and a clamp - on disposable, which contains a proprietary therapeutic transducer • D esigned to prevent bacterial docking, colonization and biofilm on indwelling urinary catheters, decrease UT and urine i
Slide 5: UroShield - Competitive Advantage
NASDAQ : NAOV Disposable clip - on accessory for urinary catheter, designed to prevent urinary catheter related complications • Helps p revent bacterial colonization and biofilm formation • Helps prevent blockage of the catheter • Helps prevent bacterial infection - UTI • Helps r educe pain, spasm,
Slide 6: UroShield – Initial Proof of Concept Studies
UroShield – Initial “Proof of Concept” Studies NASDAQ: NAOV Case Studies & RCT’s • Salem Academic Hospital HD1 - Double Blind, RCT, (22 patients) - Statistically significant indication of prevention of biofilm, - Less medications and less pain than the control (U.Ikinger) • Salem Academic Hospital H
Slide 7: Current Randomized Trial
NASDAQ: NAOV Current Randomized Trial • 55 subjects evaluated at five different nursing facilities 26 patients treated with placebo devices (“controlled”) 29 patients had active UroShield devices (“treatment”) • All patients had been treated for at least one incident of a catheter - acquired urinary
Slide 8: Understanding and controlling urinary catheter-associated biofilms: a complex problem
“Understanding and controlling urinary catheter - associated biofilms: a complex problem” Sandra A. Wilks 1,2 1 School of Health Sciences, 2 School of Biological Sciences, Faculty of Environmental & Life Sciences Contact: S.A.Wilks@soton.ac.uk Lecturer in Medical Microbiology Presented at Knowlex IP
Slide 9: Biofilms and catheters
Biofilms and catheters • Biofilms can develop on the external or internal surface of the catheter. • Can contribute to catheter - associated UTIs and catheter blockages. • Often infections and blockage can reoccur. • Up to 50% patients undergoing long - term catheterisation will experience encrustat
Slide 10: Controlled laboratory modelling
Scheme of artificial bladder model assembly: 1, aspirator with artificial urine; 2, peristaltic pump; 3, glass artificial bladder; 4, heating jacket; 5, water bath; 6, drainage bag; 7, artificial urethra. (Kazmierska et al ., 2010). Images taken from Maierl et al., 2015. This is the most widely acce
Slide 11: Lab model results
Lab model results: 0 20 40 60 80 100 120 Tip 48h Mid 48h End 48h Percentage decrease 48 h Escherichia coli UroShield % decrease compared with untreated control 0 20 40 60 80 100 120 Tip 48h Mid 48h End 48h Percentage decrease 48 h Proteus mirabilis UroShield % decrease compared with untreated contro
Slide 12: Conclusions of In Vitro Study
Conclusions of In Vitro Study • Previous testing concluded that coated and impregnated catheters were deemed innecfective • Bacteria attach to the catheter surface rapidly and after only 2 hours, are surrounded by material which is polysaccharide - based. • Complex crystalline biofilms can develop q
Slide 13: UroShield Shows Great Promise in the Effort to Reduce CAUTI
UroShield Shows Great Promise in the Effort to Reduce CAUTI!!! Summary Conclusion
Slide 14: Company Contact
Brian Murphy, CEO, Contact Info : bmurphy@nanovibronix.com 630 - 338 - 5022 Company Contact: NanoVibronix Inc. Email: info@nanovibronix.com Phone: 914 - 233 - 3004 Thank You